Furthermore, we demonstrated that renal fibrosis was attenuated by decreasing mitochondrial ROS and NLRP3 inflammasome production and TGFβ1 activation with MitoTEMPO, a selective mitochondrial-targeted antioxidant, and MCC950, a specific NLRP3 inhibitor. The gene discussed is TGFB1; the disease is renal fibrosis.